We also found that ABC-Myc cells were sensitive to mTOR and MEK inhibitors, tyrosine kinase inhibitors, HDAC inhibitors and proteasome inhibitors, consistent with our CRISPR screening data showing that mTOR, EGFR, HDAC3, and proteasome are essential, indicating that these inhibitors may have clinical potential to treat hepatoblastoma patients. This evidence concerns the gene MAP2K7 and hepatoblastoma.